健脾祛湿方对实验性重症肌无力大鼠的免疫调节作用的研究
|
摘要
重症肌无力(Myasthenia Gravis,MG)是人类的一种由针对神经肌肉接头突触后膜上乙酰胆碱受体(AChR)的自身抗体介导的器官特异自身免疫疾病,其临床表现主要有部分或骨骼肌易疲劳,呈波动性肌无力,具体活动后加重、休息后减轻和晨轻暮重等,约1%的MG患者可出现肌无力危象,抢救不及时,可引起死亡。
健脾祛湿方是导师刘友章教授临床长期用于治疗重症肌无力的中药复方,临床治疗MG患者,效果明显。为探讨健脾祛湿方的免疫调节作用的机理,我们用皮下注射鼠源性AchR-α亚基97～116肽段方法,建立实验性自身免疫性重症肌无力模型。展开T细胞及其亚群及细胞因子的研究。
目的:探讨健脾祛湿方对实验性自身免疫性重症肌无力大鼠的治疗机理。
方法:用皮下注射鼠源性AchR-α亚基97～116肽段方法,建立实验性自身免疫性重症肌无力模型,针对MG的基本病机是脾气虚兼有湿热组成健脾祛湿方,用健脾祛湿方、强的松给大鼠灌胃4周,处死动物。利用流式细胞技术和免疫组织化学方法,分别以T细胞亚群为指标,观察健脾祛湿方、强的松对EAMG细胞免疫的影响;以IL-6、TGF-β1为指标,观察健脾祛湿方对EAMG细胞因子的影响。
结果:
模型评价:
1.Lennon临床评分达0.5～1级,且随着时间的延长肌无力症状愈加显著,至造模结束时临床评分在1级以上者占造模鼠的78.38%。
2.应用5Hz连续10次的低频电刺激检测36只造模实验鼠,共有32只大鼠第1与第5个电位的衰减百分比超过10%,平均为(20.42±4.45),其余4只大鼠的电衰减率小于10%,而对照组最大衰减均不超过10%
中药干预后:
模型组AchR-Ab含量明显增高,与正常组相比具有显著差异(P＜0.01);进行药物干预后,AchR-Ab含量均较模型组明显降低(P＜0.05),但健脾清热祛湿方低剂量组AchR-Ab含量均明显高于强的松组(P＜0.05)。健脾清热祛湿方高剂量组与西药组比较差异无统计学意义(P＞0.05)。
模型组IL-6含量明显增高,与正常组相比差异有统计学意义(P＜0.05);进行药物干预后,IL-6含量均较模型组明显降低(P＜0.05),但健脾祛湿方低剂量组IL-6含量均明显高于强的松组(P＜0.05)。健脾祛湿方高剂量组与低剂量组比较差异无统计学意义(P＞0.05)。
模型组TGF-β1含量明显降低,与正常组相比具有差异(P＜0.05);进行药物干预后,TGF-β1含量均较模型组明显增加(P＜0.05),但健脾祛湿方高低剂量组TGF-β1含量均低于强的松组(P＜0.05)。健脾祛湿方高剂量组与低剂量组比较差异无统计学意义(P＞0.05)。健脾祛湿方低剂量组与正常组比较差异无统计学意义。
CD4~+%的比较:强的松组与模型组比较差异有统计学意义(P＜0.05);模型组与正常组相比具有差异无统计学意义(P＞0.05);健脾祛湿方高剂量组与低剂量组比较差异无统计学意义(P＞0.05)。正常组与健脾祛湿方高、低剂量组比较,差异有统计学意义(P＜0.05)。强的松组与健脾祛湿方高、低剂量组比较,差异有统计学意义(P＜0.05)
CD8~+%的比较:正常组与强的松组比较差异有统计学意义(P＜0.05);强的松组与中药低剂量组比较差异有统计学意义(P＜0.05)。
CD4~+/CD8~+的比较:正常组与健脾祛湿方高、低剂量组比较,差异有统计学意义(P＜0.05)。强的松组与健脾祛湿方高、低剂量组比较,差异有统计学意义(P＜0.05)
结论:
1、用皮下注射鼠源性AchR-α亚基97～116肽段可成功制作EAMG模型。
2、健脾祛湿方能改善EAMG的肌无力症状。健脾祛湿方能升高EAMG大鼠CD4~+/CD8~+比值,强的松则减低比值。强的松、健脾祛湿方均能改善EAMG症状,降低AchR-Ab浓度值,降低IL-6水平,健脾祛湿方能使EAMG大鼠TGF-β1接近正常。强的松、健脾祛湿方治疗EAMG的机理是不一致的,强的松是通过免疫抑制来改善EAMG的肌无力症状,而健脾祛湿方则是通过提高免疫来改善肌无力症状的
可见,健脾祛湿方通过影响T细胞和其亚群及细胞因子,调控细胞免疫和体液免疫,起到治疗MG的作用。
Myasthenia gravis(MG) is a T cell-regulated,antibody-mediated autoimmune disease.Impaired neuromuscular transmission characteristic of MG results from antibodies against the nicotinic acetylcholine receptor(AchR) of skeletal muscle.Experimental autoimmune myasthenia gravis(EAMG)is a well-established animal model for human myasthenia gravis(MG).The IL-6, TGF-β1,CD4~+/CD8~+,might be involved in the developed of both MG and EAMG,while TGF-β1may have suppressive effect in both diseases.
Jianpiqushi Prescription is an effective herbal prescription to treat Myasthenia gravis(MG).Jianpiqushi Prescription has been used to treat thousands of MG cases and got good result.This thesis,which establishing EAMG model in rats and focusing on cytokines IL-6,TGF-β1 etc,to studied the functional mechanism of Jianpiqushi Prescription preventing from MG.
Objective:Studied the therapeutic mechanism of Jianpiqushi Prescription to EAMG.
Method:To investigate the influence of Jianpiqushi Prescription to experimental autoimmune myasthenia gravis(EAMG).Lewis rats were immunized with Torpedo-derived 97-116 peptide of the AchRα-subunit in CFA.After the third immunization,the rats' weights,symptoms,activities electromyograms were observed to judgement the EAMG Model were succeed made.Then these succeed made EAMG model were administered by Prednisone and Jianpiqushi Prescription,and killed after 4 weeks.By using the flowcytometric analysis and immunohistochemical technique,the effects of the Jianpiqushi Prescription and Prednisone on the T lymphocyte and T lymphocyte subgroups of the EAMG of rats were observed respectively.The effect of Jianpiqushi Prescription and Prednisone on the EAMG cytokines was observed by examining the index of IL-6, TGF-β1,AchR-Ab.
Results:
model judgement:
There were 32 successful EAMG models of 39 Lewis rats.EAMG models were easy to fatigue.The weights of them reduced.The results of the percentage of decrement of RNS had significent differenc from normal rats.
The results of the effect of Jianpiqushi Prescription and Prednisone on the EAMG were as below:
Jianpiqushi PrescriPtion could improve clinical symptoms,increase body weight,increase the titers of TGF-β1 and decrease titers of AChR-Ab、IL-6,comparing from the model group.
The AchR-Ab indexes were no significent differences between Jianpiqushi Prescription in high dosage group and Prednisone group.Compared with Prednisone grou,the levets of AchR-Ab of Jianpiqushi Prescription in low dosage group were heightened.
Effect of Jianpiqushi Prescription on cytokine of EAMG rats: Compared with CFA group,levels of IL-6 of model group were heightened remarkably,P＜0.01.Compared with Prednisone grou,the levels of IL-6 of Jianpiqushi Prescription in low dosage group were heightened。The IL-6 indexes were no significent differences between Jianpiqushi Prescription in high dosage group and low dosage group.
Compared with CFA group,levels of TGF-β1 of model group were declined. Compared with Prednisone grou,the levels of TGF-β1 of Jianpiqushi Prescription in high and low dosage group were both declined.The TGF-β1 indexes were no significent differences between Jianpiqushi Prescription in high dosage group and low dosage group.
The ratio of CD4~+:
Compared with Prednisone grou,the ratio of CD4~+ of model group were heightened.The ratio of CD4~+ were no significent differences between model group and CFA group.There were no significent differences between Jianpiqushi Prescription in high dosage group and low dosage group.
The ratio of CD8~+:
Compared with Prednisone group,the ratio of CD8~+ of model group were heightened.
Compared with Prednisone group,the ratio of CD8~+ of Jianpiqushi Prescription in low dosage group were heightened.
Compared with Jianpiqushi Prescription in high dosage group and low dosage group,the ratio CD4~+/CD8~+ of the CFA group was decreased significantly.
Conclusions:Jianpiqushi Prescription can improve the lack strength of muscles and regulate the Tlymphocyte and antibody immunological function through impacting on the Tlymphocyte and Tlymphocyte subgroup and cell factor to treat MG.Jianpiqushi Prescription could increased the ratio of CD4~+/CD8~+,but Prednisone was decreased.Prednisone could more decreased the levels of IL-6 and AchR-Ab than the Jianpiqushi Prescription.Jianpiqushi Prescription could increased the levels of TGF-β1 to normal.
健脾祛湿方是导师刘友章教授临床长期用于治疗重症肌无力的中药复方,临床治疗MG患者,效果明显。为探讨健脾祛湿方的免疫调节作用的机理,我们用皮下注射鼠源性AchR-α亚基97～116肽段方法,建立实验性自身免疫性重症肌无力模型。展开T细胞及其亚群及细胞因子的研究。
目的:探讨健脾祛湿方对实验性自身免疫性重症肌无力大鼠的治疗机理。
方法:用皮下注射鼠源性AchR-α亚基97～116肽段方法,建立实验性自身免疫性重症肌无力模型,针对MG的基本病机是脾气虚兼有湿热组成健脾祛湿方,用健脾祛湿方、强的松给大鼠灌胃4周,处死动物。利用流式细胞技术和免疫组织化学方法,分别以T细胞亚群为指标,观察健脾祛湿方、强的松对EAMG细胞免疫的影响;以IL-6、TGF-β1为指标,观察健脾祛湿方对EAMG细胞因子的影响。
结果:
模型评价:
1.Lennon临床评分达0.5～1级,且随着时间的延长肌无力症状愈加显著,至造模结束时临床评分在1级以上者占造模鼠的78.38%。
2.应用5Hz连续10次的低频电刺激检测36只造模实验鼠,共有32只大鼠第1与第5个电位的衰减百分比超过10%,平均为(20.42±4.45),其余4只大鼠的电衰减率小于10%,而对照组最大衰减均不超过10%
中药干预后:
模型组AchR-Ab含量明显增高,与正常组相比具有显著差异(P＜0.01);进行药物干预后,AchR-Ab含量均较模型组明显降低(P＜0.05),但健脾清热祛湿方低剂量组AchR-Ab含量均明显高于强的松组(P＜0.05)。健脾清热祛湿方高剂量组与西药组比较差异无统计学意义(P＞0.05)。
模型组IL-6含量明显增高,与正常组相比差异有统计学意义(P＜0.05);进行药物干预后,IL-6含量均较模型组明显降低(P＜0.05),但健脾祛湿方低剂量组IL-6含量均明显高于强的松组(P＜0.05)。健脾祛湿方高剂量组与低剂量组比较差异无统计学意义(P＞0.05)。
模型组TGF-β1含量明显降低,与正常组相比具有差异(P＜0.05);进行药物干预后,TGF-β1含量均较模型组明显增加(P＜0.05),但健脾祛湿方高低剂量组TGF-β1含量均低于强的松组(P＜0.05)。健脾祛湿方高剂量组与低剂量组比较差异无统计学意义(P＞0.05)。健脾祛湿方低剂量组与正常组比较差异无统计学意义。
CD4~+%的比较:强的松组与模型组比较差异有统计学意义(P＜0.05);模型组与正常组相比具有差异无统计学意义(P＞0.05);健脾祛湿方高剂量组与低剂量组比较差异无统计学意义(P＞0.05)。正常组与健脾祛湿方高、低剂量组比较,差异有统计学意义(P＜0.05)。强的松组与健脾祛湿方高、低剂量组比较,差异有统计学意义(P＜0.05)
CD8~+%的比较:正常组与强的松组比较差异有统计学意义(P＜0.05);强的松组与中药低剂量组比较差异有统计学意义(P＜0.05)。
CD4~+/CD8~+的比较:正常组与健脾祛湿方高、低剂量组比较,差异有统计学意义(P＜0.05)。强的松组与健脾祛湿方高、低剂量组比较,差异有统计学意义(P＜0.05)
结论:
1、用皮下注射鼠源性AchR-α亚基97～116肽段可成功制作EAMG模型。
2、健脾祛湿方能改善EAMG的肌无力症状。健脾祛湿方能升高EAMG大鼠CD4~+/CD8~+比值,强的松则减低比值。强的松、健脾祛湿方均能改善EAMG症状,降低AchR-Ab浓度值,降低IL-6水平,健脾祛湿方能使EAMG大鼠TGF-β1接近正常。强的松、健脾祛湿方治疗EAMG的机理是不一致的,强的松是通过免疫抑制来改善EAMG的肌无力症状,而健脾祛湿方则是通过提高免疫来改善肌无力症状的
可见,健脾祛湿方通过影响T细胞和其亚群及细胞因子,调控细胞免疫和体液免疫,起到治疗MG的作用。
Myasthenia gravis(MG) is a T cell-regulated,antibody-mediated autoimmune disease.Impaired neuromuscular transmission characteristic of MG results from antibodies against the nicotinic acetylcholine receptor(AchR) of skeletal muscle.Experimental autoimmune myasthenia gravis(EAMG)is a well-established animal model for human myasthenia gravis(MG).The IL-6, TGF-β1,CD4~+/CD8~+,might be involved in the developed of both MG and EAMG,while TGF-β1may have suppressive effect in both diseases.
Jianpiqushi Prescription is an effective herbal prescription to treat Myasthenia gravis(MG).Jianpiqushi Prescription has been used to treat thousands of MG cases and got good result.This thesis,which establishing EAMG model in rats and focusing on cytokines IL-6,TGF-β1 etc,to studied the functional mechanism of Jianpiqushi Prescription preventing from MG.
Objective:Studied the therapeutic mechanism of Jianpiqushi Prescription to EAMG.
Method:To investigate the influence of Jianpiqushi Prescription to experimental autoimmune myasthenia gravis(EAMG).Lewis rats were immunized with Torpedo-derived 97-116 peptide of the AchRα-subunit in CFA.After the third immunization,the rats' weights,symptoms,activities electromyograms were observed to judgement the EAMG Model were succeed made.Then these succeed made EAMG model were administered by Prednisone and Jianpiqushi Prescription,and killed after 4 weeks.By using the flowcytometric analysis and immunohistochemical technique,the effects of the Jianpiqushi Prescription and Prednisone on the T lymphocyte and T lymphocyte subgroups of the EAMG of rats were observed respectively.The effect of Jianpiqushi Prescription and Prednisone on the EAMG cytokines was observed by examining the index of IL-6, TGF-β1,AchR-Ab.
Results:
model judgement:
There were 32 successful EAMG models of 39 Lewis rats.EAMG models were easy to fatigue.The weights of them reduced.The results of the percentage of decrement of RNS had significent differenc from normal rats.
The results of the effect of Jianpiqushi Prescription and Prednisone on the EAMG were as below:
Jianpiqushi PrescriPtion could improve clinical symptoms,increase body weight,increase the titers of TGF-β1 and decrease titers of AChR-Ab、IL-6,comparing from the model group.
The AchR-Ab indexes were no significent differences between Jianpiqushi Prescription in high dosage group and Prednisone group.Compared with Prednisone grou,the levets of AchR-Ab of Jianpiqushi Prescription in low dosage group were heightened.
Effect of Jianpiqushi Prescription on cytokine of EAMG rats: Compared with CFA group,levels of IL-6 of model group were heightened remarkably,P＜0.01.Compared with Prednisone grou,the levels of IL-6 of Jianpiqushi Prescription in low dosage group were heightened。The IL-6 indexes were no significent differences between Jianpiqushi Prescription in high dosage group and low dosage group.
Compared with CFA group,levels of TGF-β1 of model group were declined. Compared with Prednisone grou,the levels of TGF-β1 of Jianpiqushi Prescription in high and low dosage group were both declined.The TGF-β1 indexes were no significent differences between Jianpiqushi Prescription in high dosage group and low dosage group.
The ratio of CD4~+:
Compared with Prednisone grou,the ratio of CD4~+ of model group were heightened.The ratio of CD4~+ were no significent differences between model group and CFA group.There were no significent differences between Jianpiqushi Prescription in high dosage group and low dosage group.
The ratio of CD8~+:
Compared with Prednisone group,the ratio of CD8~+ of model group were heightened.
Compared with Prednisone group,the ratio of CD8~+ of Jianpiqushi Prescription in low dosage group were heightened.
Compared with Jianpiqushi Prescription in high dosage group and low dosage group,the ratio CD4~+/CD8~+ of the CFA group was decreased significantly.
Conclusions:Jianpiqushi Prescription can improve the lack strength of muscles and regulate the Tlymphocyte and antibody immunological function through impacting on the Tlymphocyte and Tlymphocyte subgroup and cell factor to treat MG.Jianpiqushi Prescription could increased the ratio of CD4~+/CD8~+,but Prednisone was decreased.Prednisone could more decreased the levels of IL-6 and AchR-Ab than the Jianpiqushi Prescription.Jianpiqushi Prescription could increased the levels of TGF-β1 to normal.
引文
[1]曾升海,田惠民.邓铁涛教授治疗重症肌无力的经验介绍[J].陕西中医,2000;21(12):559-560.
[2]刘小斌.强肌健力口服液治疗脾胃气虚型重症肌无力的临床观察[J].中药新药与临床药理,2004;9:361-363.
[3]刘友章,宋雅芳,蓝海,等.重症肌无力脾虚湿热病机探析[J].中华中医药学刊,2008;26(2):229-230
[4]张海龙,赵晓刚,彭玉英.中医辨证论治重症肌无力经验[J].中国医药指南,2008;6(1):208-209.
[5]石卫东.中医辨证治疗重症肌无力20例[J].光明中医,2008;23(10):1484
[6]宋水清.六味地黄丸加减治疗重症肌无力1例[J].吉林中医药,2007;9:49.
[7]张宏伟,左淑英,刘丽.从肝论治重症肌无力63例体会[J].现代中西医结合杂志,2002:11(4):337.
[8]刘炳凯,曹蓓蓓.曹鸣高治疗痿证的经验[J].四川中医,2000;18(12):1-2.
[9]苏卫东,杨晓黎.从肝论治重症肌无力的几点看法[J].辽宁中医杂志,200532(10):1022-1023.
[10]许凤全.吴以岭教授从奇经和络脉论治重症肌无力经验撷萃[J].四川中医,2006;24(2):4-6.
[11]刘会武.张静生治疗重症肌无力经验介绍[J].江苏中医药,2006;10:41-42.
[12]张正海.风引汤治重症肌无力一则[J].河南中医,1997:17(1):48.
[13]谢孔缓,赵来泗.升肌灵治疗顽固性重症肌无力40例[J].中医杂志,1999;40(12):750
[14]刘维,李相中.资生振痞丸治疗重症肌无力疗效观察[J].黑龙江中医药,2000;(5):30-31.
[15]刘少云.尚尔寿教授诊治重症肌无力经验摭拾[J].中医药学刊,2001;19(14):306
[16]王养富.中药灌肠疗法治疗重症肌无力体会[J].中国医药学报,2000;15(5):79.
[17]李顺民.健脾益肝法合雷公藤多甙片治疗重症肌无力验案一则[J].湖南中医药导报,1999;5(3):27.
[18]黄坤强,王灵萍,万毅,等.复肌宁胶囊治疗重症肌无力70例临床观察[J].中国中西医结合杂志,1998;18(12):743-744.
[19]陈金亮,许凤全.从奇经论治重症肌无力120例临床报告[J].黑龙江中医 药,2000;(2):28-29.
[20]王雅娟.从“治痿独取阳明”论针刺治疗重症肌无力[J].实用中医内科杂志,2008;22(3):
[21]盛伟,李冬梅.重症肌无力的辨证治疗探析[J].实用中医内科杂志.2003;17(2):83.
[22]冯起国,崔红,林立泉,等.合谷刺法为主治疗眼肌型重症肌无力47例中国针灸[J].1998;18(1):33-34
[23]伍渠林.针灸配单味黄芪治疗重症肌无力案[J].中华综合临床医学杂志,2008,10(4):78
[24]魏扬震,魏九康.针灸治疗重症肌无力26例[J].中国针灸,1999;19(6):345-346.
[25]王曙辉.温电针治疗重症肌无力102例疗效观察[J].中国针灸,1999;19(9):517-518.
[26]张德墓,张隽.眼针结合穴位注射治疗重症眼肌无力12例[J].上海针灸杂志,1996;15(1):9.
[27]赫群,丁新艳.重症肌无力的中医治疗[J].中国中医眼科杂志,2002;12(1):59-61.
[28]陈健文.穴位注射治疗重症肌无力眼肌型58例[J].南京中医学院学报,1995;11(1):40.
[29]夏跃胜.循经灸加复痿丸对眼肌型重症肌无力的疗效观察[J].中国中医眼科杂志,1996;6(3):185
[30]乞国艳.中西医结合治疗重症肌无力的临床观察[J].中国临床医生杂志,2007;5:57-59.
[31]王曙辉,杨明山.中西医结合治疗重症肌无力52例[J].中国中西医结合杂志,1999;19(7):438-439.
[32]魏佳军,张吴,杨明山,等.重症肌无力的中西医结合治疗[J].中国康复,2008;23(4):255-256
[33]殷宪岑.中西医结合治疗重症肌无力28例[J].山东中医杂志,2001;20(4):228-229.
[34]王律,李庚和,邹学超.重症肌无力手术治疗与中医辨证分型的关系[J].中国中西医结合杂志,1995;15(9):525-527.
[35]京明,姜京玲,姜京平.针刺为主中西药物为辅治疗重症肌无力120例[J].湖南中医学院学报,1999,19(2):57-58.
[36]邓中光.对重症肌无力的认识[J].新中医,1988;4:1
[37]邓中光,邱仕君.邓铁涛对重症肌无力的认识与辨证论治[J].中国医药学报,1993:8(2):41.
[38]李顺民.邓铁涛治疗重症肌无力的思路与方法[J].中国医药学报,1991;(3):54.
[39]蒋方建,李庚和,陆安康.中西医结合救治10例重症肌无力危象分析[J].中西医结合实用临床急救,1998;5(6):252-255.
[40]陈灏珠.实用内科学[M].北京:人民卫生出版社,2001年11月第11版:2490
[41]Vincent A.Immunology of disorders of neuromuscular transmission.Acta Neurol Scand Suppl.2006;183:1-7.
[42]许贤豪.重症肌无力[M].北京:中国协和医科大学出版社,2003年6月第1版:29
[43]李衍滨.益筋方治疗重症肌无力的实验研究[M].2006年博士学位论文.
[44]SimPson JA.Myasthenia gravis:A new hyPothesis[J].Scott MedJ,1960;(5):419-436.
[45]Rash JE,Albuquerque EX,Hudson CS,et al.Studies of human myasthenia gravis:electrophysiological and ultrastructural evidence compatible with antibody attAChment to acetylchdine receptor complex[J].Proc Natl Acad sci USA,1976:73:4584-4588.
[46]Fambrough DM,Draclullan DB,Satyamurtis.Neuromuscular junction in myasthenia gravis:decreased acetylchdine receptors[J].Science,1973;182:293-295.
[47]Engel AG,Lambert EH,Howard,FM..Immune complexes(lgG and C3)at the motor End-plate in myasthenia gravis:ultrastructural and light microscopic localization and Electrophysiologic correlations[J].Mayo Clin proc,1977;52:267-280.
[48]Ciafaloni E,Sanders DB.Advances in myasthenia gravis[J].Curr Neurol Neurosci Rep,2002;2(1):89.
[49]黄如训,梁秀玲,刘悼霖,等.临床神经病学[M],北京:科学技术出版社,1999;416-417.
[50]Im SH,Barch D,Feferman T,et al.Protective molecular mimicry in exPetimental Myasthenia gravis[J].J Neuroimmunol,2002;126(1-2):99-106
[51]Vincent A,Willcox N,Hill M,et al..Determinant spreading and immune responses to acetylchdine receptors in myasthenia gravis[J],lmmunol Rev,1998;164:157-168.
[52]Sims GP,Shiono H,Willcox N,et al.Somatic hypermutationand selection of B cells in Thymic germinal centers responding to acetylchdine receptors in myasthenia gravis[J].J Immunol,2001;167(4):1935-1944.
[53]陈清棠,余宗颐,等.临床神经病学 第一版.北京:北京科学技术出版社,2000:780-785
[54]Mossman S,VincentA,Newsom-Davis J.Myasthenia gravis without acetylcholine Receptor antibody:a distinct disease entlty[J].hancet,1996;1:116-119.
[55]Kami A,Zisman E,Katz-Levy,et al.Reactivity of Tcells from seronegative Patients With myasthenia gravis to T cells of the human acetylcholine receptor[J].Neurology,1997;48:1638-1642-
[56]Soliven BC,Lange DJ,Perm AS,et al.Seronegative myasthenia gravis[J]Neurology,1988;38(4):514-517.
[57]Kuks TB,Limburg PC,Horst G,et al.Antibodies to skeletal muscle in myasthenia Gravis.Part2.Prevalence in non-thymoma patients[J].Neurol sci,1993;120(1):75-81.
[58]Bufler J,Pitz R,CzeP M,et a].Purified IgG from seropositive and seronegative with Patients with myasthenia gravis reversibly blocks currents through nicotinine Acetylcholine receptor channels[J].Ann Neurol,1998:43(4):458-464.
[59]Oostethuis HJ,Kuks JB,et al.Myasthenia gravis syndromes[J].Curr Opin Neuro Neurosurg,1992;5(5):638-644.
[60]Christadoss P,Lindstrom JM,ralal N,et al.Immune response gene control of Iymphocyte proliferation induced by acetylcholine receptor-specific helper factor derived from lymPhocytes of myastheniac mice[J].Immunol,1986;137(6):1845-1849.
[61]王炜,吕传真,肖保国.重症肌无力四种突触前后膜结合蛋白抗体的检测[J].中国神经精神疾病杂志,1996;22(3):132-134.
[62]赖祥青,杨明山.重症肌无力患者免疫发病机制的研究[J].中国病理生理杂,2001;17(7):662.
[63]Xu TH,Ding J,Shi YL,et al.Effects ofmyastheniagravis patients sera with different Antibodies on slow k+ current at mouse motor nerve teminals[J].Neuro ires,2003:25:58-62.
[64]Mohan S,Barohn RJ,Krolick KA.Unexpected crossreacting between myosin and a Main irnmunogenic region(MIR)of the Acetycholine receptor by antisera obtained From myasthenia gravis patients[J].Clin Immunol Immunopath,1994;70:266.
[65]胡学强,江滢.重症肌无力的免疫学和遗传学进展[J].临床内科杂志,2005;22(6):364-366.
[66]McConville J,Farrugia ME,Beeson D,et al.Detection and characterization of MuSK antibodies in seronegative myasthenia gravis[J].Ann Neurol,2004;55(4):580-584.
[67]Inoue M,Fulli Y,Okmura M,et al.Mature CD4 simge positive thymocyte in human thymama:T cell may differentiate in the thymic epithelial cell tumor pathohiology-Neurology,1997;65:216-222.
[68]Rapoport B,Portolano S,MclAChlan SM,et al.Combinational libraries:new insight into Organ-specific autoantibodies[J].Immunol Today,1995;16:43-49.
[69]Melms A,Schalka BCG,Kirchner TH,et al.Thymus in myasthenia gravis.Isolation of T-lymphocyte lines specified for the nicotinic acetylcholine receptor from thymus of myasthenia gravis[J].Jclin Invest,1988;81:902-908.
[70]MAChl M.Subsets of peripheral blood lymphocytes,and thymic lymphoid cells in MG Analysis by fluorocytometry with monoclonal antibodies[J]Fukuka IgakuZasshi,1986;77:241-252.
[71]周鸣生,陈平,龚其美,等.重症肌无力患者T细胞亚群的测定[J].华西医科大学学报,1990;21:298-300.
[72]许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000:107.
[73]许蕾,朱一飞,哈志远.重症肌无力患者细胞免疫水平的检测及临床意义[J].脑与神经疾病杂志,2002;10(4):222.
[74]孙宏,郭红,许贤豪,等.重症肌无力患者外周血乙酰胆碱受体特异性T细胞s IL-2R、INF-γ、IL-4的表达和转录[J].中华神经科杂志,1998;31:79-82.
[75]Huang D,Pirkanen R,Hielmstrom P,et al.Polymorphisms in IL-1 beta and IL-1receptor antagonist genes are associated with myasthenia gravis[J]Neuroimmunol,1998;81(1-2):76-81.
[76]Emi]ie D,Crevon MC,Cohen-Kaminsky,et al.In situ production off interleukins in hyperplastic thymus from myasthenia gravis patients[J].Hum Pathol,1991;22(5):461-468.
[77]Utsugisawa K,Nagane Y,Tohgi H.Marked increase in CD44-highly Positive cells in Hyperplastic thymuses from patients with myasthenia gravislJ].Muscle Nerve,2000;23(4):507-513.
[78]Confalonieri P,Antozzi C.Immune activation in myasthenia gravis:soluble interleukin-2 recceptor,interferon-gamma and tumor necrosis factor-alpha levels in patients serum[J].Neuroimmunol,1993;48(1):33-36.
[79]Link H,Xiao BG.Rat model as to develop new immunotherapies[J].Immunol Rev,2001;184:117-128.
[80]Asthana D,Fujii Y,Huston CE,et al.Regulation of antibody production by helper T cell Clones in experimental autoimmune myasthenia gravis is mediated by IL-4 andantigen-specificT cell factors[J].Immunol Immunopathol,1993;67(3):240-248.
[81]Weissert R,Melms A,Link H.Altered tumor growdth factor beta mRNA expression is Associated with thyinectomy-related clinial remission in myastbenia gravis[J]Neurol Sci,1997;151(1):49-55.
[82]Shimada K,Kch CS.Yanagisawa[J].Arerugi,1993;42:934.
[83]Huang DR,Zhou YH,Xia SQ,et al.Markers in the promotor region of interleukin-10(IL-10) gene in myasthenia gravis:implications of divers effects of IL-10 in the pathogenesis of the disease[J].Neuroimmunol,1999;94:82-87.
[84]KarAChunski PI,Ostlie NS,Monfardini C,et al.Absence of IFN-gama or IL-12has Different effects on experimental myasthenia gravisin C57BL/6mice[J]lmmunol,2000;164(10):5236-5244.
[85]MoiolaL,GalbiatiF,MartionG,et al.IL-12 is invoIved in the induction of experimental Autoimmune myasthenia gravis,an antibody-mediated disease..Eur J Immunol,1998;28(8):2487-2499.
[86]Matusevicius D,Navikas V,Palasik W,et al.Tumor necrosis factor,lymphotoxin,linterleukin(IL)-6,IL-10,IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmentedi in myasthenia gravis[J]J Neuro immunol,1996;71:191-198.
[87]王炜,南振鹏.干扰素-γ对重症肌无力患者自身抗体的调节作用及相关分析[J].中国神经免疫和神经病学杂志,2000;7(4):234-236.
[88]Link J,Fredrikson S,Soderstrom M,et al.Organ-specific autoantigens induce transforming growth factor-βmRNA expression in mononuclear cells in Multiple sclerosis and myasthenia gravis.Annals of Neurology.1994;35:197
[89]Link J,He B,Navikas V,et al.Transforming growth factor-β1 suppress autoantigen induced expression of proinflam motorycytokins but not interleukin-10 in multiple sclerosis and myasthenia gravis.J Neuroimmunol,1997;58:21
[90]许贤豪.重症肌无力[M].见:许贤豪主编.神经免疫学[M].北京医科大学中国协和医科大学联合出版社,1992:113-130.
[91]Schluesener HJ.Transforming growth factor-β1 and β2 suppress rat astrocyte autoantigen presentation and an'tagonize hyperonduation of class major histocompatibility complex antigen expression by interferotx-γand tumor necrosis factor-α[J].J Neuroimmunol.1990;27:41.
[92]M a CG,Zhang GX,Xiao BG,et al.Cellular mRNA expression of IFN-γ,IL-4 and TGF-β in rats nasally tolerized against experimental autoimmune myasthenia gravis[J].Clin Exp Immunol,1996;104:509.
[93]张栩,孙兆林,等。重症肌无力病人外周血单个核细胞TGF-β及IL-6水平的测定[J].青岛大学医学院学报2003;12(39):386-388
[94]吕传真.重症肌无力[A].见:史玉泉主编.实用神经病学[M].第2版.上海科学技术出版社,1994:880-887.
[95]匡培根.神经系统疾病药物治疗学[M].北京:人民卫生出版社.2002:852.
[96]张志学,灵芝.新斯的明试验与重复低频刺激对重症肌无力诊断意义的比较[J].内蒙古医学杂志,2008;40(5):559-560
[97]许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000:139-151
[98]解燕春,李承晏.重症肌无力治疗新进展[J].临床内科杂志,2005;22(6):374-376.
[99]Richman DP,Agius MA.Treatment of autoimmune myasthenia gravis[J].Neurology 2003;61:1652-1661.
[100]Richman DP,Agius MA.Treatment Principles in the management of autoimmune myasthenia gravis[J].Ann NY Acad Sci,2003;998:473-480.
[101]Keesey JC.Clinical evaluation and management of myasthenia gravis[J].Muscle Nerve,2004;29:484-505.
[102]吴跃刚.大剂量免疫球蛋白联合大剂量甲基强的松龙治疗重症肌无力临床观察[J].实用医学杂志,2008;24(9):1618-1619
[103]Schulenburg A,Haas M,Goldammer A,et al.Autologous stem cell transplantation for refractory myasthenia gravi.Bone Marrow Trans plantation,2002;29:4720.
[104]Yoshinobu lwasaki,Shuji Ohsugi,Yoshizumi Takemura,et al.Muhidisclplinary Iherapy including high-dose chemotherapy followed by peripheral blood stem cell transplantation for invasive thymoma.Chest, 2002;122:2249.
[105]刘仕林.重症肌无力的发病因素及其诊治现状[J].儿科药学杂志,2007;13(5):61-63
[106]Paas-Rozaer M,Dayan M,Paas Y,et al.Oral Administration of a dual analog of two myasthenogenic T cell epitopes down regulates experimental autoimmune Myasthenia gravisin mice[J].Proc Natl Acad Sci USA,2000;97(5):2168-2173.
[107]徐浩鹏,孙曼雾,周廷冲,丁氏双鳍电鳐电器官烟碱样乙酰胆碱受体的分离提纯[J].生物化学与生物物理学报,1984;16(1)::50-55.
[108]韩涛,周勇,王旭丹,等.用我国海域电鳐电器官提取的N2-AChR粗提物建立大鼠EAMG模型[J].上海免疫学杂志,2003;23(3):163.
[109]Bellone M,Ostlie N,Lei S,et al.The 1-Abm12 mutation,which confers resistance toexperimental myasthenia gravis,drastically affects the epitope repertoire of murine CD4+cells sensitized to nicotinic acetylcholine receptor[J].J Immunol,1991;147:1484-1491.
[110]Lennon VA,Griesmann GA,McCormick DJ,et al.Definition of myasthenogenic Sites of the Human acetylcholine Receptor Using Synthetic Peptides[J].Ann NY Acad Sci,1987;505:439-450.
[111]杨丽,程焱.乙酰胆碱受体α亚单位125-147段多肽致实验性自身免疫性重症肌无力[J].中华神经科杂志,2003;36(1):32-34.
[112]Baggi F,Annoni A,Ubiali F,et al.Immunization with rat-,but not Torpedo-derived 97-116 peptide of the AChR alpha-subunit induces experimental myasthenia gravis in Lewis rat[J].Ann N Y Acad Sci,2003;998:391-394.
[113]许文华,韩莹莹,汪思应,等.鼠源乙酰胆碱受体α亚基97-116肽段免疫Lewis 鼠诱导实验性重症肌无力模型[J].中国神经精神疾病杂志,2006;32:179-180.
[114]Lennon VL,Lindstrom JM,Seybold ME.Experimental autoimmune myasthenia:a model of myasthenia gravis rats and guinea pigs.J Exp Med,1975;141(6):1365-1372.
[115]Deng C,Goluszko E,Tuzun E,et al.Resistance to experimental autoimmune myasthenia gravis in IL-6-dificient mice is associated with reduced germinal center formation and C3 production.J Immunol,2002;169(2):1077-1083.
[116]Sanders DB,Schleifer hS,Eldefrawi ME,et al.An immunologically induced defect of neuromuscular transmission in rats and rabbits.Ann NY Acad Sci,1976;274:319-336.
[117]王云甫,孙圣刚,曹学兵,等.实验性重症肌无力大鼠模型研究[J].中国神经免疫学和神经病学杂志,2003;10(4):242-245.
[118]陈奇.中药药理实验方法[M].北京:人民卫生出版社,1994:206.
[119]吴怀国,陈荣志,许文华,等.乙酰胆碱受体α亚基125～147肽段制作实验性重症肌无力动物模型的研究[J].临床神经病学研究,2006;19(5):368-370.
[120]金硕果,刘福友,等.瘫痿胶囊对自身免疫性重症肌无力小鼠血清白细胞介素4及转化生长因子β1的影响[J].中医杂志,2008;49(11):1028-1030
[121]Yarilin D,Duan R.Huang YM,et al.Dendritic cells exposed in vitro to TGF-β1 ameliorate experimental autoimmune myasthenia gravis[J].Clin Exp Immuno],2002;127(2):214-219.
[122]李秀华,程焱,杨丽,等.免疫抑制剂对重症肌无力病人T淋巴细胞亚型的影响[J].中国实用神经疾病杂志,2008;11(5):1-3
[123]李衍滨,李春红.益筋方对实验性重症肌无力小鼠T细胞及IL-2的影响[J].中华全科医学,2009;7(3):226-227
[124]陈凯佳,庞震苗.痿证(重症肌无力)患者生存质量探讨[J].辽宁中医药大学学报,2008;10(2):22-23
[125]刘莎,符州.黄芪的免疫调节作用及其临床应用[J].国际中医中药杂志,2006;28(4):203.
[126]茅苏萍,程凯灵,周韵芬.黄芪对单疱病毒性角膜炎患者Th1/Th2细胞因子调节作用[J].中国中西医结合杂志,2004;24(2):121-12
[127]蔡小燕,许艳丽,林小军.黄芪对红斑狼疮细胞凋亡和T淋巴细胞群的影响[J].实用医学杂志,2006;22(9):1077-1079
[128]张小梅.黄芪多糖的免疫调节作用及抗肿瘤作用研究进展[J].大连大学学报,2003;24(6):101-103
[129]刘春玲,徐鸿华,吴清和,等.五指毛桃对小鼠免疫功能影响的实验研究[J].中药材,2004;27(5):367-368.
[130]周添浓,王艳,等.南芪北芪抗应激与免疫调节作用的研究[J].中药新药与临床药理.2008;19(1):15-18
[131]广西壮族自治区卫生厅.广西中药材标准(1990年版)[S]南宁:广西科学技术出版社,1992:162
[132]广东中药志编辑委员会.广东中药志(第一卷)[M]广州:广东科技出版社,1994:135
[133]周俊亮.刘友章教授诊治重症肌无力的临床经验介绍.现代中西医结合杂志,2004;13(23):3107-3108
[134]刘金民.王永炎教授治疗痿证验案2则[J].北京中医药大学学报,1995;18(2):57
[2]刘小斌.强肌健力口服液治疗脾胃气虚型重症肌无力的临床观察[J].中药新药与临床药理,2004;9:361-363.
[3]刘友章,宋雅芳,蓝海,等.重症肌无力脾虚湿热病机探析[J].中华中医药学刊,2008;26(2):229-230
[4]张海龙,赵晓刚,彭玉英.中医辨证论治重症肌无力经验[J].中国医药指南,2008;6(1):208-209.
[5]石卫东.中医辨证治疗重症肌无力20例[J].光明中医,2008;23(10):1484
[6]宋水清.六味地黄丸加减治疗重症肌无力1例[J].吉林中医药,2007;9:49.
[7]张宏伟,左淑英,刘丽.从肝论治重症肌无力63例体会[J].现代中西医结合杂志,2002:11(4):337.
[8]刘炳凯,曹蓓蓓.曹鸣高治疗痿证的经验[J].四川中医,2000;18(12):1-2.
[9]苏卫东,杨晓黎.从肝论治重症肌无力的几点看法[J].辽宁中医杂志,200532(10):1022-1023.
[10]许凤全.吴以岭教授从奇经和络脉论治重症肌无力经验撷萃[J].四川中医,2006;24(2):4-6.
[11]刘会武.张静生治疗重症肌无力经验介绍[J].江苏中医药,2006;10:41-42.
[12]张正海.风引汤治重症肌无力一则[J].河南中医,1997:17(1):48.
[13]谢孔缓,赵来泗.升肌灵治疗顽固性重症肌无力40例[J].中医杂志,1999;40(12):750
[14]刘维,李相中.资生振痞丸治疗重症肌无力疗效观察[J].黑龙江中医药,2000;(5):30-31.
[15]刘少云.尚尔寿教授诊治重症肌无力经验摭拾[J].中医药学刊,2001;19(14):306
[16]王养富.中药灌肠疗法治疗重症肌无力体会[J].中国医药学报,2000;15(5):79.
[17]李顺民.健脾益肝法合雷公藤多甙片治疗重症肌无力验案一则[J].湖南中医药导报,1999;5(3):27.
[18]黄坤强,王灵萍,万毅,等.复肌宁胶囊治疗重症肌无力70例临床观察[J].中国中西医结合杂志,1998;18(12):743-744.
[19]陈金亮,许凤全.从奇经论治重症肌无力120例临床报告[J].黑龙江中医 药,2000;(2):28-29.
[20]王雅娟.从“治痿独取阳明”论针刺治疗重症肌无力[J].实用中医内科杂志,2008;22(3):
[21]盛伟,李冬梅.重症肌无力的辨证治疗探析[J].实用中医内科杂志.2003;17(2):83.
[22]冯起国,崔红,林立泉,等.合谷刺法为主治疗眼肌型重症肌无力47例中国针灸[J].1998;18(1):33-34
[23]伍渠林.针灸配单味黄芪治疗重症肌无力案[J].中华综合临床医学杂志,2008,10(4):78
[24]魏扬震,魏九康.针灸治疗重症肌无力26例[J].中国针灸,1999;19(6):345-346.
[25]王曙辉.温电针治疗重症肌无力102例疗效观察[J].中国针灸,1999;19(9):517-518.
[26]张德墓,张隽.眼针结合穴位注射治疗重症眼肌无力12例[J].上海针灸杂志,1996;15(1):9.
[27]赫群,丁新艳.重症肌无力的中医治疗[J].中国中医眼科杂志,2002;12(1):59-61.
[28]陈健文.穴位注射治疗重症肌无力眼肌型58例[J].南京中医学院学报,1995;11(1):40.
[29]夏跃胜.循经灸加复痿丸对眼肌型重症肌无力的疗效观察[J].中国中医眼科杂志,1996;6(3):185
[30]乞国艳.中西医结合治疗重症肌无力的临床观察[J].中国临床医生杂志,2007;5:57-59.
[31]王曙辉,杨明山.中西医结合治疗重症肌无力52例[J].中国中西医结合杂志,1999;19(7):438-439.
[32]魏佳军,张吴,杨明山,等.重症肌无力的中西医结合治疗[J].中国康复,2008;23(4):255-256
[33]殷宪岑.中西医结合治疗重症肌无力28例[J].山东中医杂志,2001;20(4):228-229.
[34]王律,李庚和,邹学超.重症肌无力手术治疗与中医辨证分型的关系[J].中国中西医结合杂志,1995;15(9):525-527.
[35]京明,姜京玲,姜京平.针刺为主中西药物为辅治疗重症肌无力120例[J].湖南中医学院学报,1999,19(2):57-58.
[36]邓中光.对重症肌无力的认识[J].新中医,1988;4:1
[37]邓中光,邱仕君.邓铁涛对重症肌无力的认识与辨证论治[J].中国医药学报,1993:8(2):41.
[38]李顺民.邓铁涛治疗重症肌无力的思路与方法[J].中国医药学报,1991;(3):54.
[39]蒋方建,李庚和,陆安康.中西医结合救治10例重症肌无力危象分析[J].中西医结合实用临床急救,1998;5(6):252-255.
[40]陈灏珠.实用内科学[M].北京:人民卫生出版社,2001年11月第11版:2490
[41]Vincent A.Immunology of disorders of neuromuscular transmission.Acta Neurol Scand Suppl.2006;183:1-7.
[42]许贤豪.重症肌无力[M].北京:中国协和医科大学出版社,2003年6月第1版:29
[43]李衍滨.益筋方治疗重症肌无力的实验研究[M].2006年博士学位论文.
[44]SimPson JA.Myasthenia gravis:A new hyPothesis[J].Scott MedJ,1960;(5):419-436.
[45]Rash JE,Albuquerque EX,Hudson CS,et al.Studies of human myasthenia gravis:electrophysiological and ultrastructural evidence compatible with antibody attAChment to acetylchdine receptor complex[J].Proc Natl Acad sci USA,1976:73:4584-4588.
[46]Fambrough DM,Draclullan DB,Satyamurtis.Neuromuscular junction in myasthenia gravis:decreased acetylchdine receptors[J].Science,1973;182:293-295.
[47]Engel AG,Lambert EH,Howard,FM..Immune complexes(lgG and C3)at the motor End-plate in myasthenia gravis:ultrastructural and light microscopic localization and Electrophysiologic correlations[J].Mayo Clin proc,1977;52:267-280.
[48]Ciafaloni E,Sanders DB.Advances in myasthenia gravis[J].Curr Neurol Neurosci Rep,2002;2(1):89.
[49]黄如训,梁秀玲,刘悼霖,等.临床神经病学[M],北京:科学技术出版社,1999;416-417.
[50]Im SH,Barch D,Feferman T,et al.Protective molecular mimicry in exPetimental Myasthenia gravis[J].J Neuroimmunol,2002;126(1-2):99-106
[51]Vincent A,Willcox N,Hill M,et al..Determinant spreading and immune responses to acetylchdine receptors in myasthenia gravis[J],lmmunol Rev,1998;164:157-168.
[52]Sims GP,Shiono H,Willcox N,et al.Somatic hypermutationand selection of B cells in Thymic germinal centers responding to acetylchdine receptors in myasthenia gravis[J].J Immunol,2001;167(4):1935-1944.
[53]陈清棠,余宗颐,等.临床神经病学 第一版.北京:北京科学技术出版社,2000:780-785
[54]Mossman S,VincentA,Newsom-Davis J.Myasthenia gravis without acetylcholine Receptor antibody:a distinct disease entlty[J].hancet,1996;1:116-119.
[55]Kami A,Zisman E,Katz-Levy,et al.Reactivity of Tcells from seronegative Patients With myasthenia gravis to T cells of the human acetylcholine receptor[J].Neurology,1997;48:1638-1642-
[56]Soliven BC,Lange DJ,Perm AS,et al.Seronegative myasthenia gravis[J]Neurology,1988;38(4):514-517.
[57]Kuks TB,Limburg PC,Horst G,et al.Antibodies to skeletal muscle in myasthenia Gravis.Part2.Prevalence in non-thymoma patients[J].Neurol sci,1993;120(1):75-81.
[58]Bufler J,Pitz R,CzeP M,et a].Purified IgG from seropositive and seronegative with Patients with myasthenia gravis reversibly blocks currents through nicotinine Acetylcholine receptor channels[J].Ann Neurol,1998:43(4):458-464.
[59]Oostethuis HJ,Kuks JB,et al.Myasthenia gravis syndromes[J].Curr Opin Neuro Neurosurg,1992;5(5):638-644.
[60]Christadoss P,Lindstrom JM,ralal N,et al.Immune response gene control of Iymphocyte proliferation induced by acetylcholine receptor-specific helper factor derived from lymPhocytes of myastheniac mice[J].Immunol,1986;137(6):1845-1849.
[61]王炜,吕传真,肖保国.重症肌无力四种突触前后膜结合蛋白抗体的检测[J].中国神经精神疾病杂志,1996;22(3):132-134.
[62]赖祥青,杨明山.重症肌无力患者免疫发病机制的研究[J].中国病理生理杂,2001;17(7):662.
[63]Xu TH,Ding J,Shi YL,et al.Effects ofmyastheniagravis patients sera with different Antibodies on slow k+ current at mouse motor nerve teminals[J].Neuro ires,2003:25:58-62.
[64]Mohan S,Barohn RJ,Krolick KA.Unexpected crossreacting between myosin and a Main irnmunogenic region(MIR)of the Acetycholine receptor by antisera obtained From myasthenia gravis patients[J].Clin Immunol Immunopath,1994;70:266.
[65]胡学强,江滢.重症肌无力的免疫学和遗传学进展[J].临床内科杂志,2005;22(6):364-366.
[66]McConville J,Farrugia ME,Beeson D,et al.Detection and characterization of MuSK antibodies in seronegative myasthenia gravis[J].Ann Neurol,2004;55(4):580-584.
[67]Inoue M,Fulli Y,Okmura M,et al.Mature CD4 simge positive thymocyte in human thymama:T cell may differentiate in the thymic epithelial cell tumor pathohiology-Neurology,1997;65:216-222.
[68]Rapoport B,Portolano S,MclAChlan SM,et al.Combinational libraries:new insight into Organ-specific autoantibodies[J].Immunol Today,1995;16:43-49.
[69]Melms A,Schalka BCG,Kirchner TH,et al.Thymus in myasthenia gravis.Isolation of T-lymphocyte lines specified for the nicotinic acetylcholine receptor from thymus of myasthenia gravis[J].Jclin Invest,1988;81:902-908.
[70]MAChl M.Subsets of peripheral blood lymphocytes,and thymic lymphoid cells in MG Analysis by fluorocytometry with monoclonal antibodies[J]Fukuka IgakuZasshi,1986;77:241-252.
[71]周鸣生,陈平,龚其美,等.重症肌无力患者T细胞亚群的测定[J].华西医科大学学报,1990;21:298-300.
[72]许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000:107.
[73]许蕾,朱一飞,哈志远.重症肌无力患者细胞免疫水平的检测及临床意义[J].脑与神经疾病杂志,2002;10(4):222.
[74]孙宏,郭红,许贤豪,等.重症肌无力患者外周血乙酰胆碱受体特异性T细胞s IL-2R、INF-γ、IL-4的表达和转录[J].中华神经科杂志,1998;31:79-82.
[75]Huang D,Pirkanen R,Hielmstrom P,et al.Polymorphisms in IL-1 beta and IL-1receptor antagonist genes are associated with myasthenia gravis[J]Neuroimmunol,1998;81(1-2):76-81.
[76]Emi]ie D,Crevon MC,Cohen-Kaminsky,et al.In situ production off interleukins in hyperplastic thymus from myasthenia gravis patients[J].Hum Pathol,1991;22(5):461-468.
[77]Utsugisawa K,Nagane Y,Tohgi H.Marked increase in CD44-highly Positive cells in Hyperplastic thymuses from patients with myasthenia gravislJ].Muscle Nerve,2000;23(4):507-513.
[78]Confalonieri P,Antozzi C.Immune activation in myasthenia gravis:soluble interleukin-2 recceptor,interferon-gamma and tumor necrosis factor-alpha levels in patients serum[J].Neuroimmunol,1993;48(1):33-36.
[79]Link H,Xiao BG.Rat model as to develop new immunotherapies[J].Immunol Rev,2001;184:117-128.
[80]Asthana D,Fujii Y,Huston CE,et al.Regulation of antibody production by helper T cell Clones in experimental autoimmune myasthenia gravis is mediated by IL-4 andantigen-specificT cell factors[J].Immunol Immunopathol,1993;67(3):240-248.
[81]Weissert R,Melms A,Link H.Altered tumor growdth factor beta mRNA expression is Associated with thyinectomy-related clinial remission in myastbenia gravis[J]Neurol Sci,1997;151(1):49-55.
[82]Shimada K,Kch CS.Yanagisawa[J].Arerugi,1993;42:934.
[83]Huang DR,Zhou YH,Xia SQ,et al.Markers in the promotor region of interleukin-10(IL-10) gene in myasthenia gravis:implications of divers effects of IL-10 in the pathogenesis of the disease[J].Neuroimmunol,1999;94:82-87.
[84]KarAChunski PI,Ostlie NS,Monfardini C,et al.Absence of IFN-gama or IL-12has Different effects on experimental myasthenia gravisin C57BL/6mice[J]lmmunol,2000;164(10):5236-5244.
[85]MoiolaL,GalbiatiF,MartionG,et al.IL-12 is invoIved in the induction of experimental Autoimmune myasthenia gravis,an antibody-mediated disease..Eur J Immunol,1998;28(8):2487-2499.
[86]Matusevicius D,Navikas V,Palasik W,et al.Tumor necrosis factor,lymphotoxin,linterleukin(IL)-6,IL-10,IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmentedi in myasthenia gravis[J]J Neuro immunol,1996;71:191-198.
[87]王炜,南振鹏.干扰素-γ对重症肌无力患者自身抗体的调节作用及相关分析[J].中国神经免疫和神经病学杂志,2000;7(4):234-236.
[88]Link J,Fredrikson S,Soderstrom M,et al.Organ-specific autoantigens induce transforming growth factor-βmRNA expression in mononuclear cells in Multiple sclerosis and myasthenia gravis.Annals of Neurology.1994;35:197
[89]Link J,He B,Navikas V,et al.Transforming growth factor-β1 suppress autoantigen induced expression of proinflam motorycytokins but not interleukin-10 in multiple sclerosis and myasthenia gravis.J Neuroimmunol,1997;58:21
[90]许贤豪.重症肌无力[M].见:许贤豪主编.神经免疫学[M].北京医科大学中国协和医科大学联合出版社,1992:113-130.
[91]Schluesener HJ.Transforming growth factor-β1 and β2 suppress rat astrocyte autoantigen presentation and an'tagonize hyperonduation of class major histocompatibility complex antigen expression by interferotx-γand tumor necrosis factor-α[J].J Neuroimmunol.1990;27:41.
[92]M a CG,Zhang GX,Xiao BG,et al.Cellular mRNA expression of IFN-γ,IL-4 and TGF-β in rats nasally tolerized against experimental autoimmune myasthenia gravis[J].Clin Exp Immunol,1996;104:509.
[93]张栩,孙兆林,等。重症肌无力病人外周血单个核细胞TGF-β及IL-6水平的测定[J].青岛大学医学院学报2003;12(39):386-388
[94]吕传真.重症肌无力[A].见:史玉泉主编.实用神经病学[M].第2版.上海科学技术出版社,1994:880-887.
[95]匡培根.神经系统疾病药物治疗学[M].北京:人民卫生出版社.2002:852.
[96]张志学,灵芝.新斯的明试验与重复低频刺激对重症肌无力诊断意义的比较[J].内蒙古医学杂志,2008;40(5):559-560
[97]许贤豪.神经免疫学[M],武汉:湖北科学技术出版社,2000:139-151
[98]解燕春,李承晏.重症肌无力治疗新进展[J].临床内科杂志,2005;22(6):374-376.
[99]Richman DP,Agius MA.Treatment of autoimmune myasthenia gravis[J].Neurology 2003;61:1652-1661.
[100]Richman DP,Agius MA.Treatment Principles in the management of autoimmune myasthenia gravis[J].Ann NY Acad Sci,2003;998:473-480.
[101]Keesey JC.Clinical evaluation and management of myasthenia gravis[J].Muscle Nerve,2004;29:484-505.
[102]吴跃刚.大剂量免疫球蛋白联合大剂量甲基强的松龙治疗重症肌无力临床观察[J].实用医学杂志,2008;24(9):1618-1619
[103]Schulenburg A,Haas M,Goldammer A,et al.Autologous stem cell transplantation for refractory myasthenia gravi.Bone Marrow Trans plantation,2002;29:4720.
[104]Yoshinobu lwasaki,Shuji Ohsugi,Yoshizumi Takemura,et al.Muhidisclplinary Iherapy including high-dose chemotherapy followed by peripheral blood stem cell transplantation for invasive thymoma.Chest, 2002;122:2249.
[105]刘仕林.重症肌无力的发病因素及其诊治现状[J].儿科药学杂志,2007;13(5):61-63
[106]Paas-Rozaer M,Dayan M,Paas Y,et al.Oral Administration of a dual analog of two myasthenogenic T cell epitopes down regulates experimental autoimmune Myasthenia gravisin mice[J].Proc Natl Acad Sci USA,2000;97(5):2168-2173.
[107]徐浩鹏,孙曼雾,周廷冲,丁氏双鳍电鳐电器官烟碱样乙酰胆碱受体的分离提纯[J].生物化学与生物物理学报,1984;16(1)::50-55.
[108]韩涛,周勇,王旭丹,等.用我国海域电鳐电器官提取的N2-AChR粗提物建立大鼠EAMG模型[J].上海免疫学杂志,2003;23(3):163.
[109]Bellone M,Ostlie N,Lei S,et al.The 1-Abm12 mutation,which confers resistance toexperimental myasthenia gravis,drastically affects the epitope repertoire of murine CD4+cells sensitized to nicotinic acetylcholine receptor[J].J Immunol,1991;147:1484-1491.
[110]Lennon VA,Griesmann GA,McCormick DJ,et al.Definition of myasthenogenic Sites of the Human acetylcholine Receptor Using Synthetic Peptides[J].Ann NY Acad Sci,1987;505:439-450.
[111]杨丽,程焱.乙酰胆碱受体α亚单位125-147段多肽致实验性自身免疫性重症肌无力[J].中华神经科杂志,2003;36(1):32-34.
[112]Baggi F,Annoni A,Ubiali F,et al.Immunization with rat-,but not Torpedo-derived 97-116 peptide of the AChR alpha-subunit induces experimental myasthenia gravis in Lewis rat[J].Ann N Y Acad Sci,2003;998:391-394.
[113]许文华,韩莹莹,汪思应,等.鼠源乙酰胆碱受体α亚基97-116肽段免疫Lewis 鼠诱导实验性重症肌无力模型[J].中国神经精神疾病杂志,2006;32:179-180.
[114]Lennon VL,Lindstrom JM,Seybold ME.Experimental autoimmune myasthenia:a model of myasthenia gravis rats and guinea pigs.J Exp Med,1975;141(6):1365-1372.
[115]Deng C,Goluszko E,Tuzun E,et al.Resistance to experimental autoimmune myasthenia gravis in IL-6-dificient mice is associated with reduced germinal center formation and C3 production.J Immunol,2002;169(2):1077-1083.
[116]Sanders DB,Schleifer hS,Eldefrawi ME,et al.An immunologically induced defect of neuromuscular transmission in rats and rabbits.Ann NY Acad Sci,1976;274:319-336.
[117]王云甫,孙圣刚,曹学兵,等.实验性重症肌无力大鼠模型研究[J].中国神经免疫学和神经病学杂志,2003;10(4):242-245.
[118]陈奇.中药药理实验方法[M].北京:人民卫生出版社,1994:206.
[119]吴怀国,陈荣志,许文华,等.乙酰胆碱受体α亚基125～147肽段制作实验性重症肌无力动物模型的研究[J].临床神经病学研究,2006;19(5):368-370.
[120]金硕果,刘福友,等.瘫痿胶囊对自身免疫性重症肌无力小鼠血清白细胞介素4及转化生长因子β1的影响[J].中医杂志,2008;49(11):1028-1030
[121]Yarilin D,Duan R.Huang YM,et al.Dendritic cells exposed in vitro to TGF-β1 ameliorate experimental autoimmune myasthenia gravis[J].Clin Exp Immuno],2002;127(2):214-219.
[122]李秀华,程焱,杨丽,等.免疫抑制剂对重症肌无力病人T淋巴细胞亚型的影响[J].中国实用神经疾病杂志,2008;11(5):1-3
[123]李衍滨,李春红.益筋方对实验性重症肌无力小鼠T细胞及IL-2的影响[J].中华全科医学,2009;7(3):226-227
[124]陈凯佳,庞震苗.痿证(重症肌无力)患者生存质量探讨[J].辽宁中医药大学学报,2008;10(2):22-23
[125]刘莎,符州.黄芪的免疫调节作用及其临床应用[J].国际中医中药杂志,2006;28(4):203.
[126]茅苏萍,程凯灵,周韵芬.黄芪对单疱病毒性角膜炎患者Th1/Th2细胞因子调节作用[J].中国中西医结合杂志,2004;24(2):121-12
[127]蔡小燕,许艳丽,林小军.黄芪对红斑狼疮细胞凋亡和T淋巴细胞群的影响[J].实用医学杂志,2006;22(9):1077-1079
[128]张小梅.黄芪多糖的免疫调节作用及抗肿瘤作用研究进展[J].大连大学学报,2003;24(6):101-103
[129]刘春玲,徐鸿华,吴清和,等.五指毛桃对小鼠免疫功能影响的实验研究[J].中药材,2004;27(5):367-368.
[130]周添浓,王艳,等.南芪北芪抗应激与免疫调节作用的研究[J].中药新药与临床药理.2008;19(1):15-18
[131]广西壮族自治区卫生厅.广西中药材标准(1990年版)[S]南宁:广西科学技术出版社,1992:162
[132]广东中药志编辑委员会.广东中药志(第一卷)[M]广州:广东科技出版社,1994:135
[133]周俊亮.刘友章教授诊治重症肌无力的临床经验介绍.现代中西医结合杂志,2004;13(23):3107-3108
[134]刘金民.王永炎教授治疗痿证验案2则[J].北京中医药大学学报,1995;18(2):57
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |